(Note: the fusion was discovered by NGS. Many chromosome rearrangement mechanisms such as translocation, inversion,deletion or complex rearrangement may lead to the same fusion)
Note
Non-annotated chromosomal abnormality. Preliminary data :
if you are an author who wish to write a full paper/card on this translocation,go to u00a0How to contribute
Summary
Note
Non-annotated chromosomal abnormality. Preliminary data :
if you are an author who wish to write a full paper/card on this translocation,go to How to contribute
if you are an author who wish to write a full paper/card on this translocation,go to How to contribute
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 33996558 | 2021 | Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. | 169 |
| 36154696 | 2022 | The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications. | 119 |
| 36428521 | 2022 | Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma. | 102 |
| 30372397 | 2018 | Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. | 70 |
| 23644518 | 2013 | Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. | 62 |
| 28212566 | 2017 | Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. | 61 |
| 30660076 | 2019 | Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. | 56 |
| 39036450 | 2022 | The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma. | 45 |
| 35875073 | 2022 | Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review. | 41 |
| 33823929 | 2021 | Association between visceral adiposity and DDX11 as a predictor of aggressiveness of small clear-cell renal-cell carcinoma: a prospective clinical trial. | 41 |
| 31963294 | 2020 | Gene Expression Analysis of Aggressive Clinical T1 Stage Clear Cell Renal Cell Carcinoma for Identifying Potential Diagnostic and Prognostic Biomarkers. | 36 |
| 38933491 | 2023 | Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition. | 35 |
| 32392781 | 2020 | Prediction of High-Grade Clear Cell Renal Cell Carcinoma Based on Plasma mRNA Profiles in Patients with Localized Pathologic T1N0M0 Stage Disease. | 34 |
| 30962867 | 2019 | Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers. | 33 |
| 27751729 | 2017 | Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. | 30 |
| 37427096 | 2023 | Genomic profiles of renal cell carcinoma in a small Chinese cohort. | 28 |
| 23036577 | 2013 | Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. | 27 |
| 28408295 | 2017 | Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. | 27 |
| 26300218 | 2016 | Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. | 20 |
| 26166446 | 2015 | BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. | 0 |
| 33664427 | 2021 | New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. | 0 |
| 32561872 | 2020 | Genomic profiling in renal cell carcinoma. | 0 |
| 27890923 | 2017 | The epigenetic landscape of renal cancer. | 0 |
| 29426696 | 2018 | Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. | 0 |
| 24166983 | 2014 | Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. | 0 |
| 39910301 | 2025 | A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. | 0 |
| 37661782 | 2023 | Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas. | 0 |
| 25365943 | 2014 | Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. | 0 |
| 27664394 | 2016 | Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. | 0 |
| 39746268 | 2025 | The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy. | 0 |
| 22805307 | 2012 | Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. | 0 |
| 39693721 | 2025 | Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 26928227 | 2016 | Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. | Bueno R et al |
Citation
Jean-Loup Huret ; Philippe Dessen
PBRM1/BAP1 (3p21)
Atlas Genet Cytogenet Oncol Haematol. 0000-00-00
Online version: http://atlasgeneticsoncology.org/solid-tumor/105806/deep-insight-explorer/meetings/tumors-explorer/humanGenome
